Trial Profile

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary) ; Zanubrutinib (Primary)
Indications B-cell leukaemia; B-cell lymphoma
Focus Adverse reactions; Registrational
Acronyms BGB-3111-LTE1
Sponsors BeOne Medicines

Most Recent Events

12 Dec 2023 Results (N=47) containing ad hoc analysis of ibrutinib-tolerant patients from ASPEN study (NCT03053440) at ≥1 yr from initiation of zanubrutinib in this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
28 Jun 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com